Erythema nodosum caused by goserelin acetate sustained-release : Case report and literature review
© 2023 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd..
Goserelin acetate is a gonadotropin-releasing hormone analog that is commonly used in patients with prostate cancer, endometriosis, and precocious puberty. The side effects of the drug include allergic rash, flushing, excessive sweating, skin swelling at the injection site, sexual dysfunction, erectile dysfunction, and menopausal symptoms. However, erythema nodosum has so far not been reported. In this paper, we have presented the case of erythema nodosum caused by goserelin acetate and a review of the literature on its adverse effects, thus providing useful insights into clinical management and medication safety.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
International journal of rheumatic diseases - 26(2023), 10 vom: 10. Okt., Seite 2055-2059 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Meng, Fanyu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
0F65R8P09N |
|---|
| Anmerkungen: |
Date Completed 10.10.2023 Date Revised 10.10.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/1756-185X.14692 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356184684 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356184684 | ||
| 003 | DE-627 | ||
| 005 | 20231226065926.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/1756-185X.14692 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1187.xml |
| 035 | |a (DE-627)NLM356184684 | ||
| 035 | |a (NLM)37114900 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Meng, Fanyu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Erythema nodosum caused by goserelin acetate sustained-release |b Case report and literature review |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.10.2023 | ||
| 500 | |a Date Revised 10.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd. | ||
| 520 | |a Goserelin acetate is a gonadotropin-releasing hormone analog that is commonly used in patients with prostate cancer, endometriosis, and precocious puberty. The side effects of the drug include allergic rash, flushing, excessive sweating, skin swelling at the injection site, sexual dysfunction, erectile dysfunction, and menopausal symptoms. However, erythema nodosum has so far not been reported. In this paper, we have presented the case of erythema nodosum caused by goserelin acetate and a review of the literature on its adverse effects, thus providing useful insights into clinical management and medication safety | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a adverse drug reactions | |
| 650 | 4 | |a erythema nodosum | |
| 650 | 4 | |a goserelin acetate implant | |
| 650 | 7 | |a Goserelin |2 NLM | |
| 650 | 7 | |a 0F65R8P09N |2 NLM | |
| 650 | 7 | |a Delayed-Action Preparations |2 NLM | |
| 700 | 1 | |a Su, Rong |e verfasserin |4 aut | |
| 700 | 1 | |a Ling, Li |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Weitian |e verfasserin |4 aut | |
| 700 | 1 | |a Du, Shiyu |e verfasserin |4 aut | |
| 700 | 1 | |a Peng, Jiangyun |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Weichao |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of rheumatic diseases |d 2009 |g 26(2023), 10 vom: 10. Okt., Seite 2055-2059 |w (DE-627)NLM197180566 |x 1756-185X |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2023 |g number:10 |g day:10 |g month:10 |g pages:2055-2059 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/1756-185X.14692 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2023 |e 10 |b 10 |c 10 |h 2055-2059 | ||